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Abstract
Background: The human immunodeficiency virus type 1 (HIV-1) proviral DNA persists in infected
cells, even after prolonged successful HAART. In the present study, a relative quantification assay
of HIV-1 proviral DNA by LightCycler® real-time PCR based on SYBR Green I detection was
developed in comparison to the number of purified CD4+ cells as estimated by the quantification
of the β-globin gene.
Methods: The ability of the designed gag primers to quantify HIV-1 Group M and the PCR
efficiency were assessed on HIV-1 reference isolate subtypes A, B, C and D. The 8E5 cell line
containing a single defective copy of HIV-1 proviral DNA was used as a standard for both the HIV-
1 target gene and the β-globin reference gene. The assay was applied on thirty consecutive patient
samples received for RNA viral load determinations and on retrospective samples from fifteen
patients undergoing 2 years of structured treatment interruption (STI).
Results: The lower limit of quantification was 50 HIV-1 DNA proviral copies per CD4+ cell
sample. The dynamic range was from 50 to 106 HIV-1 DNA copies per CD4+ cell sample with intra-
and inter-assay coefficients of variability ranging from 3.1% to 37.1%. The β-globin reference gene
was quantified down to a limit of 1.5 pg of DNA/µl (approximately 5 cells) with intra- and interassay
coefficients of variability ranging from 1.8% to 21%. DNA proviral load varies widely among HIV-1
infected patients. Proviral load and plasma viral load rebound were high in STI patients who took
longer to achieve an undetectable plasma viral load under therapy. A statistically significant
correlation was observed between DNA proviral load and RNA steady state viral load in STI
patients (p-value = 0,012).
Conclusion: We have developed a fast, sensitive and specific relative quantification assay of HIV-
1 proviral DNA in purified CD4+ cells. The assay enables the monitoring of HIV-1 proviral load,
which may be useful to monitor therapy efficacy especially in patients with undetectable plasma
RNA viral load, and allows the exploration of viral reservoirs.
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At present, HIV-1 infected patients are followed by moni-
toring plasma HIV-1 RNA viral load, allowing follow up
of the immediate effects of treatment, and CD4+ T cell
count, allowing initiation or reinitiation of the therapy as
immune function decreases [1]. The HIV-1 proviral DNA
load could be an alternative viral marker, as it is known
that proviral DNA persists in infected cells, even after pro-
longed successful HAART as evidenced by undetectable
plasma RNA viral load. A decline in DNA might indicate
a long-term impact of the HAART on the reservoirs and
the long-term effectiveness of the treatment [2-11]. But
data regarding the decline in DNA are sometimes conflict-
ing. Some authors noted decreased levels after one year of
antiretroviral triple combination therapy [12] and others
reported stable HIV-1 DNA levels over several years in PI-
ART naive patients [13,14]. Several assays for the quantifi-
cation of HIV type 1 proviral DNA in peripheral blood
mononuclear cells (PBMC) have previously been
reported, and many of them are based either on the prin-
ciple of conventional PCR requiring post PCR analysis or
on real-time PCR on total PBMC, using specific probe
detection [9,10,15-23]. Recently, a multiplex real-time
PCR for quantification of HIV-1 DNA and the human
albumin gene in CD4+ cells has been published [23]
using TaqMan probes and an Epstein-Barr virus (EBV)
standard curve. Sequence-specific hybridisation probes
provide the most specific real-time analysis of amplified
target sequences but the very high variability of HIV
sequences within subtypes, even in HIV variants in a given
patient, led us to choose a sequence-independent detec-
tion with SYBR Green I. One of the experimental prereq-
uisites for relative quantification consists in having
identical PCR efficiencies for both target gene and refer-
ence gene in sample, standard, and calibrator. PCR effi-
ciency may vary between EBV standard PCR and HIV-1
PCR. We therefore used the 8E5 cell line containing a sin-
gle defective copy of HIV-1 proviral DNA as a standard for
both the HIV-1 target gene and the β-globin reference
gene in order to carry out a relative quantification.
Another recent publication described a real-time PCR
based on LightCycler® technology revealed through SYBR
green fluorochrome to quantify the HIV-1 proviral DNA
load[24]. The article describes quantification in PBMC of
HIV-1 seropositive patients. As 95 to 99% of infected cells
are CD4+ cells[25], we developed a relative quantification
assay of HIV-1 proviral DNA in purified CD4+ cells on the
LightCycler® by real-time PCR compared to cell quantifica-
tion by β-globin PCR.
Methods
Primer design and selection
Several primers were designed in the gag-pol junction
region with low variability on the basis of a consensus
sequence obtained by aligning complete sequences of
HIV-1 subtypes A to J from the Entrez nucleotides data-
base [26]. The Vector NTI® Suite (InforMax, Bethesda,
USA) software was used for the design of primers. Selec-
tion of primer sets was first based on a specific signal with-
out primer dimer formation when testing DNA from 8E5
cell dilution series and negative controls. Primer and
MgCl2 concentrations were optimised by combining
primer concentrations ranging from 0.3 mM to 1.2 mM
and MgCl2 concentrations from 2 mM to 5 mM. The
selected primers were tested on DNA samples obtained
from HIV-1 subtypes A, B, C, and D reference strains and
from clinical samples including subtypes B and non-B. We
also tested the absence of signal with HIV-2 DNA. The
final primer set selection was based on the efficiency of
the PCR reaction. Differences in efficiency may have a
major impact on the calculation of the initial amount. In
theory, the optimum efficiency in PCR is two, meaning
that every PCR product is replicated once every cycle. In
reality, however, many PCR parameters influence PCR
efficiency which is calculated according to the formula E =
10-1/slope. The LightCycler® Software calculates the slope of
the standard curve by plotting crossing points against the
logarithm of concentration for each standard point of a
10-fold dilution series. A slope value of -3.33 indicates the
maximal PCR efficiency.
Reference strains and patients
Four different reference strains of HIV-1 and 2 of HIV-2
from the National Institute for Biological Standards and
Control (NIBSC, UK) were used in this project: HIV-1 Pri-
mary isolates-Uganda (HIV-1 subtype A, NIBSC reposi-
tory reference ARP177.5) [27], 8E5/LAV (HIV-1 subtype
B, NIBSC repository reference ARP110) [28], HIV-1
SE12808/ SE14784 (Subtype C, NIBSC repository refer-
ence ARP197.1, ARP197.2) and HIV1-ELI (HIV-1 subtype
D, NIBSC repository reference EVA117) [29], HIV-2 ROD
reference strain (subtype A, NIBSC repository reference
EVA121.1) [30,31] and HIV-2 EHO reference strain (sub-
type B, NIBSC repository reference EVA132) [32].
Samples from 15 patients undergoing 2 years (start 2001)
of structured treatment interruption (STI) and 30 consec-
utive clinical samples received for RNA plasma viral load
determinations were included in the study. Informed con-
sent following the Helsinki declaration was obtained
from each patient. The HIV-1 seropositive status was con-
firmed according to the accepted methods. HIV-1 RNA
plasma viral load was performed using the HIV-1 Ampli-
cor™ Monitor 1.5 (Roche, Branchburg, NJ, USA). The viral
RNA and the proviral DNA sequences were determined by
using an in house RT-PCR method applied on reverse
transcriptase and protease genes [adapted from [33]]. HIV
RNA was extracted from plasma (QIAmp Viral Mini Kit™,
QIAGEN, Leiden, The Netherlands) and a direct cycle
sequencing was used with BigDye terminator chemistryPage 2 of 9
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CD4+ cells were isolated from 10 ml of patient EDTA
whole blood samples by an immunomagnetic method
using anti-CD4 coated magnetic beads (Dynabeads M450
CD4, Dynal A S, Oslo, Norway) according to the manufac-
turer's protocol and were stored at -80°C until use. The
complete process takes approximately 3 hours and the
purity of the CD4+ cell preparation was about 99% as esti-
mated by Becton Dickinson Fascan Flow Cytometer tech-
nology (data not shown). HIV-2 clinical samples were
obtained from patients who were diagnosed with HIV-2
infection at our AIDS reference laboratory. The 8E5 cell
line, the CD4+ blood donor cells infected with HIV-1 ref-
erence strains, and the H9 cell line infected with HIV-2 ref-
erence strains were cultured in RPMI 1640 medium
supplemented with 10% FetalClone 1® (HyClone, Logan,
Utah, USA), 1% Glutamine 200 mM and 0.1% Gentamy-
cin 50 mg/ml. 8E5 cells were counted by the Coulter auto-
mated haematology analyser and diluted to 106 cells per
aliquot stored at -80°C.
DNA purification
DNA was extracted from purified patient CD4+ cells
diluted in 200 µl PBS, using the High Pure® PCR Template
Preparation Kit (Roche Diagnostics GmbH, Mannheim,
Germany) according to the manufacturer's recommenda-
tions. To concentrate the HIV-1 target gene in patient sam-
ples, DNA was eluted in a volume of 50µl. DNA from the
T-lymphoblastoid 8E5 cells, and CD4+ blood donor cells
infected with HIV-1 reference strains were eluted in 200µl.
The 8E5 cell DNA was purified from 106 cells. A negative
control (template replaced by Nuclease-free water) was
included in each PCR run. Particular attention was paid to
using DNAse and RNAse free materials. Depending on the
number of samples, the whole DNA purification process
required approximately 1 hour.
HIV-1 DNA real time PCR assay
A series of ten-fold dilutions of 8E5 DNA corresponding
to 2.5 × 103 to 2.5 HIV-1 DNA copies per µl (2.5 × 103 to
2.5 cells/µl) was included in each experiment in order to
generate an external standard curve. The PCR mixture
(total volume 20 µl) in nuclease free water contained 2 µl
of LightCycler® FastStart DNA Master SYBR Green 1, a
ready-to-use "Hot Start" reaction mix (Roche Diagnostics
GmbH, Mannheim, Germany), final concentrations of 4
mM MgCl2 and 0.5µM of each primer and 5µl of purified
DNA or negative control. All samples were analysed in
duplicate. The amplification protocol for HIV-1 on the
LightCycler® was as follows: a 10 min denaturation step at
95°C for polymerase activation, a "touch down" PCR step
of 10 cycles consisting of 10 seconds (s) at 95°C, 10 s at
65°C, and 30 s at 72°C, followed by 40 cycles consisting
of 10 s at 95°C, 10 s at 55°C, and 30 s at 72°C. The fluo-
rescence was measured at the end of each elongation step.
The next step was a slow heating (0.1°C per s) of the
amplified product from 65°C to 95°C in order to gener-
ate a melting temperature curve. This curve served as a spe-
cificity control. The entire cycling process including data
analysis took less than one hour and was monitored using
the LightCycler® software program (version 3.5). Second
derivative maximum mode was chosen with baseline
adjustment set in the arithmetic mode.
A fragment from the human β-globin gene was amplified
in parallel with the HIV-1 gag gene to quantify the total
number of investigated cellular genomes. The β-globin
real-time quantitative PCR was performed using the Light-
Cycler® Control Kit DNA (Roche Diagnostics GmbH,
Mannheim, Germany) according to the manufacturer's
recommendations. The PCR mixture (total volume 20µl)
in nuclease free water contained 2µl of LightCycler® Fast-
Start DNA Master SYBR Green 1 and 2µl of LightCycler®
Control Kit DNA primer mix, 2µl of 10-fold dilution of
purified DNA or negative control, and a final concentra-
tion of 4 mM MgCl2. The DNA control from the kit corre-
sponds to 30 ng of human genomic DNA. The same 8E5
DNA standard samples corresponding to 2.5 × 103 to 2.5
cells/µl were included in each experiment in order to gen-
erate an external standard curve as for the HIV-1 experi-
ment. All samples were run in duplicate. A melting
temperature step of β-globin amplicons was performed.
To validate the use of the 8E5 cells as standards, we first
performed a real-time PCR quantification of the human β-
globin gene using the DNA control of the kit to generate a
standard curve. The values of the 8E5 cell count as per-
formed by the Coulter automated haematology analyser
were compared with the values obtained by extrapolating
the cell count from the β-globin real-time PCR quantifica-
tion. In the second step, 8E5 cells were used as standards
and we compared the kit DNA control value obtained
from the LightCycler® quantification with the theoretical
value.
Relative quantification was carried out using the LightCy-
cler® Relative quantification Software (version 1.0). The
calculation of data is based on the crossing point (Cp) val-
ues obtained by the LightCycler® Software. Results are cal-
culated as the target/reference ratio of the sample divided
by the target/reference ratio of the calibrator. This corrects
for sample inhomogeneity and variability of detection.
The result of the HIV-1 proviral quantification was
expressed as log10 number of DNA copies per 106 CD4+
cells.Page 3 of 9
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Statistical analysis was performed using the parametric
Pearson correlation test or the nonparametric Spearman
correlation method. The critical p-value required to reject
the null hypothesis (there is no proof of significant corre-
lation between the variables) and accept the alternative
hypothesis is equal to or less than 0,05.
Results
Primer selection
Out of several primers designed in the HIV-1 gag-pol junc-
tion region, the sequences of the selected HIV-1 gag for-
ward primer BK1F and the reverse primer BK1R were
respectively: 5'-GTA ATA CCC ATG TTT TCA GCA TTA TC-
3' and 5'-TCT GGC CTG GTG CAA TAG G-3'. These
amplify a 181-bp amplicon in the gag region of low varia-
bility among HIV-1 subtypes.
Standard validation
The use of 8E5 cells as standards was validated. As shown
in Figure 1, the HIV-1 and the β-globin curves generated
by using 8E5 cells had comparable slopes, indicating
equal PCR efficiency. The comparison of the 8E5 cell
count as performed by the Coulter automated haematol-
ogy analyser with the values obtained by real-time PCR
quantification of β-globin genes showed similar results, as
did the comparison of the DNA control sample value
obtained from LightCycler® quantification with the theo-
retical value (Figure 2).
Specificity of the assay
As described in the methods section, the specificity of the
PCR reaction was tested with DNA purified from the 8E5
cell line carrying a single copy of subtype B proviral DNA
per cell, with CD4+ blood donor cells infected with HIV-
1 subtype A, C, and D reference strains and with H9 cells
infected with HIV-2 ROD (subtype A) and EHO (subtype
B) reference strains. Clinical samples from HIV-1 or HIV-
2 infected patients were included. The subtyping results
based on proviral protease sequences showed 65% of sub-
type B viruses and 35% of non-subtype B viruses, which
included subtypes A, C, D, F1 and CRF AE [34].
HIV-1 amplicons produced in the PCR reaction had the
same melting temperature of 85.30°C, with a slight varia-
tion depending on the HIV-1 subtypes and on the type of
initial sample, indicating that the signal was specific. The
melting temperature of β-globin amplicons was about
86°C. Furthermore, the specificity of the HIV-1 amplifica-
tion was confirmed by the presence of the expected band
size on the electrophoresis gel (agarose 2%) carried out
with the PCR products obtained from standards, reference
strains, and patient samples. Direct sequencing of ampli-
fied products using the PCR primers showed the expected
HIV-1 sequences (data not shown). No amplification was
obtained with HIV-2 DNA purified from patient samples
and from reference strains belonging to HIV-2 subtypes A
the HIV-1 and the human globin standard curves created by a en-fold dilution series of 8E5 cell DNA show comp rable slopes, indicati g q al PCR efficiencyFigure 
the HIV-1 and the human globin standard curves created by a 
ten-fold dilution series of 8E5 cell DNA show comparable 
slopes, indicating equal PCR efficiency. The LightCycler Soft-
ware calculates the slope of the standard curve by plotting 
crossing points against the logarithm of concentration for 
each standard point. Each standard point was run in five rep-
licates. (_____) HIV-1 DNA standard curve, (_ _ _) Human 
globin standard curve.
Validation of the use of 8E5 cells as standards for human globin PCRFigure 2
Validation of the use of 8E5 cells as standards for human 
globin PCR. The figure shows similar results of the 8E5 cell 
count as performed by the Coulter automated hematology 
analyzer compared with the values obtained by real-time 
PCR quantification of the human globin gene. The compari-
son of the theoretical and calculated values of the DNA con-
trol sample from LightCycler Kit shows equal results. Each 
standard point was run in five replicates.Page 4 of 9
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NIBSC were amplified. The results showed that the assay
amplified DNA purified from HIV-1 reference isolate sub-
types A, B, C, and D with similar PCR efficiency (Table 1).
Sensitivity and reproducibility of the assay
Ten replicates of 1 copy, 5 copies, and 10 copies of DNA
purified from 8E5 cells were tested in the PCR reaction.
The detection of one HIV-1 DNA copy per PCR failed in
most cases while five and ten copies were always detected.
The lower limit of quantification was set at 5 HIV-1 DNA
proviral copies per PCR or 50 HIV-1 DNA proviral copies
per CD4+ cell sample. A HIV-1 DNA proviral load below
50 copies per CD4+ cell sample was reported as undetect-
able. The dynamic range was from 50 to 106 HIV-1 DNA
proviral copies per CD4 lymphocyte sample. We tested
the intra and inter-assay reproducibility of our technique
with a series of ten-fold dilutions of 8E5 DNA from 12.5
× 103 to 12.5 HIV-1 DNA copies per PCR. The intra-assay
reproducibility was evaluated using five replicates of each
point and the inter-assay reproducibility was calculated
on 10 runs. The intra- and inter-assay coefficients of vari-
ability of the HIV-1 DNA copy number ranged from 3.1%
for high provirus concentrations to 37.1% for low concen-
trations. The quantification of the human β-globin refer-
ence gene by using the "LightCycler® Control Kit DNA"
enabled a lower limit of detection of 1.5 pg/µl (approxi-
mately 5 cells) with intra- and interassay coefficients of
variability ranging from 1.8% for high DNA concentra-
tions to 21% for low DNA concentrations. We observed
an inhibition of the human β-globin reference gene
amplification at high amounts of the cellular genome. The
inhibition was shown by a maximum fluorescence of the
amplification curve, which was lower than the maximum
fluorescence of the standard points. In our assay, this
problem was solved by diluting (10-fold) DNA from
patient samples. The influence of the type of sample on
the PCR reaction was tested by diluting the standard 8E5
cells in HIV seronegative plasma from a blood donor
before DNA extraction. A slight difference (about 1 Cp)
was observed within the range of 12.5 to 12.5 × 103HIV-1
DNA copies per PCR between the Cp values obtained for
8E5 cells diluted in PBS buffer as compared to 8E5 cells
diluted in the plasma, in both HIV-1 and β-globin assays.
We also successfully tested the quantification of both HIV-
1 and β-globin genes without the need to include a stand-
ard curve in every run by loading an external standard
curve generated in a different run.
HIV-1 DNA viral load in clinical specimens
In order to test our quantitative real-time PCR assay on
DNA from patient CD4+ cell samples, the assay was first
applied on thirty consecutive patient samples received for
RNA viral load determinations regardless of whether or
not they were receiving antiretroviral therapy. Of the 30
patients, 10 were treatment naive while 20 were antiretro-
viral-experienced adults (Table 2). If we put all patients (N
= 30) together, no significant correlation was found
between DNA relative proviral load and either plasma
RNA viral load or CD4+ cell count (Figure 3 and Figure 4).
The only observed correlative tendency was between DNA
relative proviral load and plasma RNA viral load in the
naive patients (Figure 5), but this was not statistically sig-
nificant (p-value >0,05 by Pearson test). DNA proviral
load varies widely among HIV-1 infected patients in the
same or at different disease stages.
The assay was also applied on samples from fifteen
patients undergoing 2 years of STI (Table 2). At the start of
the STI, all patients were receiving at least a triple-therapy
regimen including two nucleoside reverse transcriptase
inhibitors (NRTIs) plus 1 or 2 PIs. All STI patients had
received previous monotherapy or dual therapy before
HAART with a mean total treatment time of five years. At
Table 1: PCR efficiencies of HIV-1 group M amplification
Sample concentration: Subtype A Subtype B Subtype C Subtype D
Log dilution Mean Cpa Mean Cp Mean Cp Mean Cp
-2 26,16 22,90 24,61 26,13
-3 29,50 26,02 28,10 29,27
-4 32,82 29,75 31,79 32,86
-5 36,72 32,98 34,83 36,72
Slopeb -3,50 -3,37 -3,43 -3,54
R2c 0,99 0,99 0,99 0,99
(a) Mean of crossing point values calculated using two replicates of each point in 3 runs.
(b) The LightCycler Software calculates the slope of the curve by plotting crossing points against the logarithm of concentration for each point of a 
10-fold dilution series. A slope value of -3.33 indicates the maximal PCR efficiency.
(c) The LightCycler Software also calculates the coefficient of correlation R2.Page 5 of 9
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1 RNA viral load of less than 50 copies/ml; four had a
baseline HIV-1 RNA viral load of less than 572 copies/ml
(median of 2 log copies/ml) and the mean CD4+ cell
count was 748 × 106 cells/l. Out of the 15 STI patients,
seven had a steady state viral load less than 3.3 log copies/
ml, including three patients with undetectable HIV-1 RNA
viral load (<50 copies/ml), while eight patients had a high
HIV-1 RNA viral load ranging from 3.9 to 4.7 log copies/
ml. All seven patients with a low steady state plasma viral
load showed a DNA proviral load under 2.5 log copies/
106 CD4+ cells, including four patients with a proviral
load under the limit of quantification (<5 DNA copies/
PCR). Of eight patients with a high steady state plasma
Table 2: Patient characteristics
Naive group Treated patients STI patients
Number 10 20 15
Genders
Males 5 8 8
Females 5 12 6
Transsexuals 1
Mean years old 42 42 43
Geographic origin
Europeans 5 12 12
Other/Unknown 5 8 3
Mean range follow up
Yearsa 4 (range 1 – 11) a 7.5 (range 1 – 15)a 6 (range 2 – 7) a
CD4+ count
cells × 106/l Median 391 (range 109–805) Median 338 (range 1 – 790) Median 717 (range 216 – 1356)
<200 cells × 106/l (Number) b 1 6 0
Plasma HIV-RNA
Log10 copies/ml Median 4.8 (range 2.7 – 5.4) Median 4.4 (range 1.7 – 5.9) Median 3.2 (range 1.7 – 4.7) c
<50 copies/ml (Number)b 0 5 3
HIV1-DNA
Log10 copies/106 CD4 cells Median 3.0 (range 2.6 – 3.7) Median 3.3 (range 2.2 – 4.6) Median 2.9 (range 2.1 – 4.0)
<5 copies/PCR (Number) b 6 12 5
(a) Number of years between HIV-1 infection diagnosis and DNA proviral load testing.
(b) Number of patients with viral or proviral load under limit of quantification or with CD4+ count <200 cells 106/l.
(c) Steady state viral load after STI.
No correlation was found between DNA proviral load and plasma RNA viral load i  thir y co secutive unselecteatient samples received for RNA viral load det rminationsFigure 3
No correlation was found between DNA proviral load and 
plasma RNA viral load in thirty consecutive unselected 
patient samples received for RNA viral load determinations.
No correlation was found between DNA proviral load and CD4+ c ll c unt in thirty consecutive unselected patient samples re eived for RNA viral load determinationsFigur  4
No correlation was found between DNA proviral load and 
CD4+ cell count in thirty consecutive unselected patient 
samples received for RNA viral load determinations.Page 6 of 9
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viral load under 2.5 log copies/106 CD4+ cells while five
had a DNA proviral load above 2.5 log copies/106 CD4+
cells. A statistically significant correlation was observed
between DNA proviral load and RNA steady state viral
load in STI patients (Figure 6). The Pearson's coefficient of
correlation was about 0,578 with an associated p-value of
0,012. When applying the nonparametric Spearman cor-
relation method, the associated p-value was about 0,018.
Proviral load and plasma viral load rebound were high in
STI patients who took longer to achieve an undetectable
plasma viral load under therapy.
Discussion
A relative quantification assay of HIV-1 proviral DNA in
purified CD4+ cells was developed on the LightCycler®
real-time PCR instrument expressed per 106 CD4+ cells as
derived from estimated by the quantification of the β-
globin gene. In healthy individuals, CD4+ cells represent
approximately 30 to 50% of the PBMC and their fraction
may be considerably lower and variable over time in HIV-
infected patients. Theoretically, to improve the sensitivity
and accuracy of an assay for low-copy-number samples, a
larger amount of DNA should be added to the PCR reac-
tion mix when purified from PBMCs than directly from
CD4+ cells. High amounts of the cellular genome may
lead to PCR inhibition. In addition, published data show
low proviral loads, ranging from 1 to < 5 log10 HIV-1 DNA
copies (median 2–3 log10) in 106 PBMC equivalents [14-
17,19,20,22-24]. Methods quantifying the HIV-1 DNA
proviral load in PBMC may therefore lead to undetectable
proviral loads. However, in any case a direct comparison
between DNA load in CD4+ cells and PBMCs could be
useful as the CD4 isolation adds extra work (i.e. costs),
which should be weighed against the clinical benefit.
Sequence-specific hybridisation probes provide the most
specific real-time analysis of amplified target sequences
but the very high variability of HIV sequences within
subtypes, even in HIV variants in a given patient led us to
choose a sequence-independent detection with SYBR
Green I. The ability of SYBR Green I to bind double-
stranded DNA molecules with emission of a fluorescent
signal allows the PCR reaction to be monitored. As SYBR
Green I binds to all double-stranded DNA molecules, a
melting temperature curve needs to be constructed to
ensure the specificity of the signal. Thus specific primer
selection and PCR optimisation is crucial to avoid primer
dimer formation. We tested the influence of possible
inhibitors in the DNA sample. A slight variation of the
melting temperature (about 1°C) and the Cp values
(about 1Cp) was observed, depending on the HIV-1
subtypes and on the type of initial sample (EDTA whole
blood or culture supernatant). The specificity of the HIV-
1 amplification was confirmed by the presence of the
expected band size on the electrophoresis gel carried out
with the PCR products from standards, reference strains,
and patient samples. Direct sequencing of amplified prod-
ucts showed the expected HIV-1 sequences. No amplifica-
tion was obtained with HIV-2 DNA. The ability of the
assay to quantify HIV-1 Group M and the PCR efficiency
were assessed on HIV-1 reference isolate subtypes A, B, C,
Correlative tendency between DNA relative proviral load and plasma RNA viral load in the naive patients but not sta-tistical y significant (p-value >0,05 by P arson est)Figure 5
Correlative tendency between DNA relative proviral load 
and plasma RNA viral load in the naive patients but not sta-
tistically significant (p-value >0,05 by Pearson test)
The assay was also applied on samples from 15 patients undergoing 2 years of STIFigu e 6
The assay was also applied on samples from 15 patients 
undergoing 2 years of STI. A statistically significant correla-
tion was observed between DNA proviral load and RNA 
steady state viral load in STI patients. (p-value = 0,012, Pear-
son correlation test)Page 7 of 9
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ular attention should be given to the quantification of the
β-globin gene. We observed an inhibition with a high
amount of the reference gene. Diluting (10-fold) DNA
from patient samples resolves this problem. The lower
limit of quantification is five HIV-1 DNA proviral copies
per PCR and 1.5 pg of cellular DNA/µl (approximately
five cells) for the human β-globin reference gene quantifi-
cation. The dynamic range of HIV-1 DNA quantification is
between 50 and 106 proviral copies per CD4 with coeffi-
cients of variability of the HIV-1 DNA copy number rang-
ing from 3.1% for high provirus concentrations to 37.1%
for low concentrations. Our method shows acceptable
technical sensitivity and specificity. Quantification could
be performed without the need to include a standard
curve in every run by loading an external standard curve
generated in a different run. Relative quantification was
carried out by using the LightCycler® Relative quantifica-
tion Software (version 1.0). The result of HIV-1 proviral
quantification was expressed as log10 number of DNA
copies per 106 CD4+ cells. The crossing points that are cal-
culated by the LightCycler® Software are a function of the
amplification efficiency. Efficiency differences have a
major impact on the accuracy of initial amount calcula-
tion. The assay developed met one of the experimental
prerequisites for PCRs, HIV-1 target gene and β-globin ref-
erence gene, i.e., having identical PCR efficiencies in sam-
ple, standard, and calibrator.
The assay was successfully tested on 30 consecutive unse-
lected patient samples. No significant correlation was
found between DNA relative proviral load and either
plasma RNA viral load or CD4+ cell in this group, overall.
Similar observations have been reported in the literature
[9,24]. DNA proviral load varies widely among HIV-1
infected patients in the same or at different disease stages.
The assay was also applied on samples from 15 patients
undergoing 2 years of STI. In fact, of the 15 STI patients,
all seven patients with a low steady state plasma viral load
showed a DNA proviral load under 2.5 log copies/106
CD4+ cells, including four patients with a proviral load
under the limit of quantification (<5 DNA copies/PCR).
Of the remaining eight patients presenting a high steady
state plasma viral load (>3.9 log copies/ml), three showed
a DNA proviral load under 2.5 log copies/106 CD4+ cells
while five had a DNA proviral load above 2.5 log copies/
106 CD4+ cells. We observed that in patients who needed
a change in antiretroviral treatment to achieve an undetec-
table plasma viral load or who took longer to achieve an
undetectable viral load under treatment, the proviral load
was >2.5 log copies/PCR and the plasma viral load
rebound was high. However, a large and prospective study
is needed to confirm the value of this observation and
particularly to assess the predictive value of proviral load
in the setting of STI.
Conclusion
We have developed a fast, sensitive and specific assay,
which enables the monitoring of HIV-1 proviral load in
CD4+ cells by LightCycler® real-time PCR based on SYBR
Green I quantification. This should enable us to evaluate
prospectively the proviral load as a prognostic marker in
therapy and in the evaluation of treatment interruptions.
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